Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

ONTX / Onconova Therapeutics, Inc. / ARMISTICE CAPITAL, LLC - 3G (Passive Investment)

6h sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No.)*     Onconova Therapeutics, Inc. (Name of Issuer)     Common Stock, par value $0.01 per share (Title of Class of Securities)     68232V306 (CUSIP Number)     February 8, 2018 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X] Rule 1 (22-0)

ONTX / Onconova Therapeutics, Inc. / ARMISTICE CAPITAL, LLC - 3G (Passive Investment)

6h sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No.)*     Onconova Therapeutics, Inc. (Name of Issuer)     Common Stock, par value $0.01 per share (Title of Class of Securities)     68232V306 (CUSIP Number)     February 8, 2018 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X] Rule 1 (22-0)

ONTX / Onconova Therapeutics, Inc. / 683 Capital Management, LLC - FEBRUARY 16, 2018 (Activist Investment)

2018-02-17 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.  20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. )* Onconova Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68232V306 (CUSIP Number) Richard Guidice, Esq. Kleinberg, Kaplan, Wolff & Cohen, P.

ONTX / Onconova Therapeutics, Inc. / 683 Capital Management, LLC - FEBRUARY 16, 2018 (Activist Investment)

2018-02-17 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.  20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. )* Onconova Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68232V306 (CUSIP Number) Richard Guidice, Esq. Kleinberg, Kaplan, Wolff & Cohen, P.

ONTX / Onconova Therapeutics, Inc. PRE 14A

2018-02-17 sec.gov
QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.          ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý   Preliminary Proxy Statement o   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o   Definitive Proxy Statem

ONTX / Onconova Therapeutics, Inc. / 683 Capital Management, LLC - FEBRUARY 16, 2018 (Activist Investment)

2018-02-17 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.  20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. )* Onconova Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68232V306 (CUSIP Number) Richard Guidice, Esq. Kleinberg, Kaplan, Wolff & Cohen, P.

ONTX / Onconova Therapeutics, Inc. / 683 Capital Management, LLC - FEBRUARY 16, 2018 (Activist Investment)

2018-02-17 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.  20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. )* Onconova Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 68232V306 (CUSIP Number) Richard Guidice, Esq. Kleinberg, Kaplan, Wolff & Cohen, P.

ONTX / Onconova Therapeutics, Inc. / TYNDALL CAPITAL PARTNERS L P - 3G/A (Passive Investment)

2018-02-15 sec.gov
  THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 1)*       Onconova Therapeutics, INC. (Name of Issuer)   Common STOCK, $0.01 par value PER SHARE (Title of Class of Securities)   68232V306 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:   [   ]   Rule

ONTX / Onconova Therapeutics, Inc. / TYNDALL CAPITAL PARTNERS L P - 3G/A (Passive Investment)

2018-02-15 sec.gov
  THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 1)*       Onconova Therapeutics, INC. (Name of Issuer)   Common STOCK, $0.01 par value PER SHARE (Title of Class of Securities)   68232V306 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:   [   ]   Rule

ONTX / Onconova Therapeutics, Inc. 424B4 (Prospectus)

2018-02-09 sec.gov
Table of Contents   Filed Pursuant to Rule 424b4 Registration No. 333-222374      PROSPECTUS     Onconova Therapeutics, Inc.   5,707,500 Units (each Unit contains one Share of Common Stock and one Warrant to purchase 0.1 Share of Series A Convertible Preferred Stock)   2,942,500 Pre-Funded Units (each Pre-Funded Unit contains one Pre-Funded Warrant to purchase one Share of Common Stock and one Warrant to purchase 0.

ONTX / Onconova Therapeutics, Inc. 8-K (Current Report)

2018-02-08 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): February 8, 2018     Onconova Therapeutics, Inc. (Exact name of Registrant as specified in its charter)     Delaware   001-36020   22-3627252 (State or Other Jurisdiction of Incorporation or Organization)   (Commission File Number)   (I.

ONTX / Onconova Therapeutics, Inc. S-1/A

2018-02-07 sec.gov
  As filed with the Securities and Exchange Commission on February 6, 2018 Registration No. 333-222374     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   AMENDMENT NO. 3 TO FORM S-l  REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933   Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Delaware   2834   22-3627252 (State or other   (Primary Standard   (I.

ONTX / Onconova Therapeutics, Inc. CORRESP (Current Report)

2018-02-06 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): February 2, 2018     Onconova Therapeutics, Inc. (Exact name of Registrant as specified in its charter)     Delaware   001-36020   22-3627252 (State or Other Jurisdiction of Incorporation or Organization)   (Commission File Number)   (I.

ONTX / Onconova Therapeutics, Inc. S-1/A

2018-02-06 sec.gov
Table of Contents   As filed with the Securities and Exchange Commission on February 5, 2018 Registration No. 333-222374       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   AMENDMENT NO. 2 TO FORM S-l REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933   Onconova Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Delaware   2834   22-3627252 (State or other jurisdiction of incorporation or organization)   (Primary Standard Industrial Class

ONTX / Onconova Therapeutics, Inc. ER

2018-01-30 sec.gov
December 4, 2017 Ramesh Kumar, Ph.D. President and Chief Executive Officer Onconova Therapeutics, Inc. 375 Pheasant Run Newtown, PA 18954 Re: Onconova Therapeutics, Inc. Registration Statement on Form S-3 Filed November 20, 2017 File No. 333-221684 Dear Dr. Kumar: We have limited our review of your registration statement to those issues we have addressed in our comment. Please respond to this letter by amending your registration statement and providing the requested in


CUSIP: 68232V116